secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001628280-23-037183
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus reports Q3 net sales $120.8M (-6.1% YoY), raises 2023 adjusted EBITDA guidance
--------------------------------------------------------------------------------

- Net loss from continuing ops improved to $8.8M from $101.0M in Q3 2022; loss per share $0.12 vs $1.18.
- Adjusted EBITDA from continuing ops $21.7M, down 0.9% YoY; non-GAAP EPS $0.05 vs $0.18.
- Pain Treatments revenue grew 3.1% YoY to $53.7M; Surgical Solutions up 5.7% in U.S.
- Raised full-year 2023 guidance: net sales $498-505M, adjusted EBITDA $84-87M.
- Restorative Therapies fell 34.8% due to Wound Business divestiture; underlying organic sales down 0.5%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023037183/0001628280-23-037183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000162828023037183/bvs-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer